Literature DB >> 28698302

Heme Modification Contributes to the Mechanism-Based Inactivation of Human Cytochrome P450 2J2 by Two Terminal Acetylenic Compounds.

Hsia-Lien Lin1, Haoming Zhang1, Vyvyca J Walker1, Jaime D'Agostino1, Paul F Hollenberg2.   

Abstract

The mechanism-based inactivation of human CYP2J2 by three terminal acetylenic compounds: N-(methylsulfonyl)-6-(2-propargyloxyphenyl)hexanamide (MS), 17-octadecynoic acid (OD), and danazol (DZ) was investigated. The loss of hydroxyebastine (OHEB) carboxylation activity in a reconstituted system was time- and concentration-dependent and required NADPH for MS and OD, but not DZ. The kinetic constants for the mechanism-based inactivation of OHEB carboxylation activity were: KI of 6.1 μM and kinact of 0.22 min-1 for MS and KI of 2.5 μM and kinact of 0.05 min-1 for OD. The partition ratios for MS and OD were ∼10 and ∼20, respectively. Inactivation of CYP2J2 by MS or OD resulted in a loss of the native heme spectrum and a similar decrease in the reduced CO difference spectrum. A heme adduct was observed in the MS-inactivated CYP2J2. The possible reactive metabolite which covalently modified the prosthetic heme was characterized by analysis of the glutathione conjugates formed by MS or OD following oxygenation of the ethynyl moiety. Liquid chromatography-mass spectrometry showed that inactivation by MS or OD did not lead to modification of apoprotein. Interaction of CYP2J2 with DZ produced a type II binding spectrum with a Ks of 2.8 μM and the IC50 for loss of OHEB carboxylation activity was 0.18 μM. In conclusion, heme modification by MS and OD was responsible for the mechanism-based inactivation of CYP2J2. The results suggest that the ethynyl moiety of MS and OD faces the heme iron, whereas the isoxazole ring of DZ is preferentially oriented toward the heme iron of CYP2J2.
Copyright © 2017 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28698302      PMCID: PMC5539586          DOI: 10.1124/dmd.117.075846

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  43 in total

1.  Involvement of CYP2J2 and CYP4F12 in the metabolism of ebastine in human intestinal microsomes.

Authors:  Takanori Hashizume; Susumu Imaoka; Masashi Mise; Yoshiaki Terauchi; Toshihiko Fujii; Hisashi Miyazaki; Tetsuya Kamataki; Yoshihiko Funae
Journal:  J Pharmacol Exp Ther       Date:  2002-01       Impact factor: 4.030

2.  Characterization of ebastine, hydroxyebastine, and carebastine metabolism by human liver microsomes and expressed cytochrome P450 enzymes: major roles for CYP2J2 and CYP3A.

Authors:  Kwang-Hyeon Liu; Mi-Gyung Kim; Dong-Jun Lee; Yune-Jung Yoon; Min-Jung Kim; Ji-Hong Shon; Chang Soo Choi; Young Kil Choi; Zeuresenay Desta; Jae-Gook Shin
Journal:  Drug Metab Dispos       Date:  2006-08-08       Impact factor: 3.922

3.  The catalytic site of rat hepatic lauric acid omega-hydroxylase. Protein versus prosthetic heme alkylation in the omega-hydroxylation of acetylenic fatty acids.

Authors:  C A CaJacob; W K Chan; E Shephard; P R Ortiz de Montellano
Journal:  J Biol Chem       Date:  1988-12-15       Impact factor: 5.157

4.  Cytochrome P450-derived arachidonic acid metabolism in the rat kidney: characterization of selective inhibitors.

Authors:  M H Wang; E Brand-Schieber; B A Zand; X Nguyen; J R Falck; N Balu; M L Schwartzman
Journal:  J Pharmacol Exp Ther       Date:  1998-03       Impact factor: 4.030

5.  Inhibition of carcinoma cell motility by epoxyeicosatrienoic acid (EET) antagonists.

Authors:  Kasem Nithipatikom; Daniel M Brody; Alan T Tang; Vijaya L Manthati; John R Falck; Carol L Williams; William B Campbell
Journal:  Cancer Sci       Date:  2010-08-27       Impact factor: 6.716

Review 6.  Role of epoxyeicosatrienoic acids in protecting the myocardium following ischemia/reperfusion injury.

Authors:  John M Seubert; Darryl C Zeldin; Kasem Nithipatikom; Garrett J Gross
Journal:  Prostaglandins Other Lipid Mediat       Date:  2006-07-10       Impact factor: 3.072

7.  Xenobiotic-metabolizing enzymes and transporters in the normal human brain: regional and cellular mapping as a basis for putative roles in cerebral function.

Authors:  Fabien Dutheil; Sandrine Dauchy; Monique Diry; Véronique Sazdovitch; Olivier Cloarec; Lucille Mellottée; Ivan Bièche; Magnus Ingelman-Sundberg; Jean-Pierre Flinois; Isabelle de Waziers; Philippe Beaune; Xavier Declèves; Charles Duyckaerts; Marie-Anne Loriot
Journal:  Drug Metab Dispos       Date:  2009-04-09       Impact factor: 3.922

8.  Role of cytochrome P450 2C8 and 2J2 genotypes in calcineurin inhibitor-induced chronic kidney disease.

Authors:  Helen E Smith; J P Jones; Thomas F Kalhorn; Federico M Farin; Patricia L Stapleton; Connie L Davis; James D Perkins; David K Blough; Mary F Hebert; Kenneth E Thummel; Rheem A Totah
Journal:  Pharmacogenet Genomics       Date:  2008-11       Impact factor: 2.089

9.  Mechanism-based inactivation of CYP2B1 and its F-helix mutant by two tert-butyl acetylenic compounds: covalent modification of prosthetic heme versus apoprotein.

Authors:  Hsia-Lien Lin; Haoming Zhang; Kathleen R Noon; Paul F Hollenberg
Journal:  J Pharmacol Exp Ther       Date:  2009-08-21       Impact factor: 4.030

10.  Identification of 17-alpha-ethynylestradiol-modified active site peptides and glutathione conjugates formed during metabolism and inactivation of P450s 2B1 and 2B6.

Authors:  Ute M Kent; Hsia-Lien Lin; Danielle E Mills; Kelly A Regal; Paul F Hollenberg
Journal:  Chem Res Toxicol       Date:  2006-02       Impact factor: 3.739

View more
  4 in total

Review 1.  Acetylenes: cytochrome P450 oxidation and mechanism-based enzyme inactivation.

Authors:  Paul R Ortiz de Montellano
Journal:  Drug Metab Rev       Date:  2019-07-07       Impact factor: 4.518

2.  Formation of Both Heme and Apoprotein Adducts Contributes to the Mechanism-Based Inactivation of Human CYP2J2 by 17α-Ethynylestradiol.

Authors:  Hsia-Lien Lin; Haoming Zhang; Paul F Hollenberg
Journal:  Drug Metab Dispos       Date:  2018-03-30       Impact factor: 3.922

Review 3.  Flipside of the Coin: Iron Deficiency and Colorectal Cancer.

Authors:  Aysegül Aksan; Karima Farrag; Sami Aksan; Oliver Schroeder; Jürgen Stein
Journal:  Front Immunol       Date:  2021-03-11       Impact factor: 7.561

4.  Role of Arginine 117 in Substrate Recognition by Human Cytochrome P450 2J2.

Authors:  Pierre Lafite; François André; Joan P Graves; Darryl C Zeldin; Patrick M Dansette; Daniel Mansuy
Journal:  Int J Mol Sci       Date:  2018-07-16       Impact factor: 5.923

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.